Knowing that mast cells express c-kit receptor and that, during our experiment they were significantly more numerous in refractory cHL than in responders, drugs inhibiting the tyrosine kinase activity of ckit, like Imatinib (Gleevec), in combination with chemotherapy might have therapeutic value in refractory c-HL (45). The gene discussed is KIT; the disease is classic Hodgkin lymphoma.